Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorFundación Pública Andaluza para la gestión de la Investigación en Sevilla
About this trial
The CLOPI-SNAP study is a randomized, multicenter, open-label clinical trial embedded within the SNAP (NCT 05137119) research platform. It constitutes a sub-study added to the core protocol for patients suffering Staphylococcus aureus bacteremia (SAB).
Eligibility criteria
Qualifiers
Microbiological isolation: Presence of Staphylococcus aureus complex in at least one blood culture.
Hospitalization status: The patient must be admitted to a participating hospital at the time of eligibility assessment.
Time window: Eligibility assessment must be completed within 72 hours after collection of the initial blood culture.
Disqualifiers
Allergies: Known hypersensitivity to thienopyridines (clopidogrel, prasugrel, ticlopidine).
Clinical status: Inability to tolerate or take oral medications, and severe hepatic impairment (Child-Pugh Class C).
Pregnancy: Pregnant or breastfeeding women.
Active or recent bleeding: Significant bleeding or invasive procedures within the previous 7 days.
Trial design
Treatments tested in this trial
- Clopidogrel
- No antiplatelet treatment
Treatment groups
230 Participants
are divided into 2 treatment groupsSponsors and collaborators
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Lead sponsor
University of Melbourne
Collaborator
Source ClinicalTrials.gov